Get the best out of your 3-D sample
Quantitative Image Evaluation

3-D Samples at multiple scales

Cells to in-vitro microtissues

Ex-vivo tissues and organs

Imaging Service

We suggest and implement the imaging strategy that best meets your needs

DISCOVER OUR WORK

Lorem Ipsum
Klorim ipsum
Blorum pipsum
3D exploration and quantification for the study of heart disease Regionalization study of the effect of active molecules on 3D cellular models Development of automated plaque tests for the characterization of molecule efficiency on 3D models of cellular multi-spheres

EXPERTISES AND SERVICES

We bring you our expertise in biology, imaging and image processing to characterize your samples and quantify the effects of your molecules.

3-D SAMPLES

  • 3-D Spheroids
  • 3-D co-culture model
  • Hypoxia culture condition

Because of the ethical and societal considerations as well as the very high cost of animal testing, in vitro 3-D models that recapitulate normal or pathological human tissues are essential for understanding the intimate mechanisms of growth and for the development of new treatments. Spheroids or micro-tissues faithfully reproduce the organization of a tissue, recapitulating the cell-cell connections, cell-microenvironment and cellular heterogeneity found in the micro-regions of a tumor or organ. They are considered attractive models to assess the anti-proliferative activity of new drugs or genotoxic properties. The activity we offer is based on our strong expertise in the development of multicellular 3D models from existing lines or from cells supplied by customers. We can support the assessment of a compound from 3D cell culture, through the processing of 3D models up to their three-dimensional exploration. We also propose culture in hypoxia and physoxia conditions of 3-D models grown either in suspension or in your scaffold.

3-D EXPLORATION

  • 3-D Imaging
  • 3-D Illustration
  • 3-D Animation

How to explore and visualize the effects of new compounds? To fully exploit the capabilities of 3-D cell models, instead of an overall assessment, it is essential to preserve the 3-D regionalization level of analysis when investigating the effect of a drug. We provide a service to explore the dynamics of regionalization and the effects of new compounds in 3D models. We will build for it on 2D and 3D microscopy technologies like the most innovative light sheet microscopy, multi-photon (available on technological service platforms of ITAV). We also provide full imaging of your samples (up to 1 cm3): micro-tissues, organelles or fragments of bodies. These samples will undergo specific preparation according to the most appropriate imaging system.

3-D QUANTITATIVE ANALYSIS

  • Tailored analysis parameters identification
  • Specific Algorithm Development
  • Customized 3-D Quantification

How to characterize quantitatively the effects of new compounds? To get the most out of the experiments and make a decision with high confidence, we must be able to rely on numbers. We offer expert service in the characterization and quantification of all acquired data, including quantification of multiparametric images. We offer criteria for an objective assessment of the effects of molecules on multiple biological parameters of cells and tissues, such as the expression of target, viability, proliferation, cell cycle, 3D organization, apoptosis, etc ...

LATEST NEWS

    2017-07-17 - Symposium Inexo 2017 - Modèles Alternatifs
    Imactiv-3D presented a complete 3D cell culture, imaging and quantification process for the evaluation of the cytotoxicity of compounds. Consult the poster in the gallery of the site: A new image analysis-based approach to evaluate cytoxicity on 3D models

WHAT THEY SAY ABOUT US


I contacted the company IMACTIV 3D based in Toulouse with the aim of imaging the ability of small molecules to protect the heart of mice from the damage of ischemia-reperfusion. The contacts with the founder and the collaborators of IMACTIV3D were easy and fluid. They were very receptive to our requests. We are, from now on, very satisfied and impressed by their results. In the long term, they will go far beyond those obtained with the approaches conventionally used in the laboratory and will prove superior in terms of information, quantification and will reduce the number of animals.

Mme Catherine Brenner-Jan

INSERM U1180-LabEx LERMIT / IPSIT-CIBLOT / Université Paris-Sud

Mme Catherine Brenner-Jan


The IMACTIV-3D company offers services for the evaluation by 3D imaging and quantitative image analysis on 3D models, tissue or organs. IMACTIV-3D offers expertise in research and development, and brings to its customers an essential support in the decision-making process. The creation and success of IMACTIV-3D demonstrates how the know-how and inventions from academic research can be valuated by starting a company.

Bernard Ducommun

Director of the Advanced Technology Institute in Life Sciences in Toulouse

Bernard Ducommun

ABOUT US

The leitmotif of the Imactiv-3D company is to meet the challenges of evaluation of active molecules:

Imactiv-3D supports pharmas and biotech companies in their development strategy, study or research on innovative and reliable predictive models to help them in their decision making. Imactiv-3D relies for this on three complementary expertise:

OUR TEAM

Valérie Lobjois

Valérie Lobjois

Associate, Scientific Council

Valérie holds a PhD from the University of Toulouse and she is lecturer in cell and developmental biology. Valérie is a cancer biology specialist, and is co-leader of the team « Innovation for the study of cell proliferation in 3D – IP3D » at the Institute of Advanced Technologies in Life sciences. She brings to the company her expertise in handling and multimodal exploration of 3D models, especially for spatial-temporal exploration by 3D imaging techniques.

Lagarde Jean-Michel

Lagarde Jean-Michel

Founder and CEO

Jean-Michel is an Engineer in optics and image analysis, graduated of the National School of Physics of Marseille in 1990. He has over 20 years experience as project manager and head of a unit research in Imaging and Engineering of the skin in the Pierre Fabre Laboratories. After a first experience as Founder and President of a first company in 2012 in the field of aid in the early detection of melanoma, he now devotes to the development of Imactiv-3D bringing his skills in imaging, image treatment and corporate management.

CONTACT